Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
he financing was significantly oversubscribed with high demand from both existing and new investors.
The transaction as well as the open offer is expected to be completed by June this year.
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
Subscribe To Our Newsletter & Stay Updated
